Journal article
Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor
Pediatric pulmonology, Vol.54(8), pp.1200-1208
08/2019
DOI: 10.1002/ppul.24341
PMCID: PMC6641998
PMID: 31012285
Abstract
The cystic fibrosis transmembrane conductance regulator (CFTR) modulators ivacaftor and lumacaftor/ivacaftor improve the status of existing infections in patients with cystic fibrosis (CF). It is unknown how well these drugs protect patients against incident infections. We hypothesized that CFTR modulator treatment would decrease new infections with Pseudomonas aeruginosa or Staphylococcus aureus.
We retrospectively studied a single-center cohort of patients with CF during two time periods (2008-2011, Era 1) and (2012-2015, Era 2) based on the January 2012 approval of ivacaftor. Using Kaplan-Meier analysis, we compared the time to any new infection with P. aeruginosa, methicillin-resistant S. aureus (MRSA), or methicillin-sensitive S. aureus (MSSA) that was absent during a 2-year baseline. We stratified the analysis based on whether patients received ivacaftor or lumacaftor/ivacaftor during Era 2. We used the log-rank test and considered P < 0.05 statistically significant.
For patients receiving ivacaftor or lumacaftor/ivacaftor in Era 2, there was a statistically significant delay in the time to new bacterial acquisition in Era 2 vs. Era 1 ( P = 0.008). For patients who did not receive CFTR modulators, there was a trend toward slower acquisition of new bacterial infections in Era 2 compared to Era 1, but this was not statistically significant ( P = 0.10).
Patients receiving ivacaftor or lumacaftor/ivacaftor for CF had significantly delayed acquisition of P. aeruginosa and S. aureus after these drugs were released. This method for analyzing incident infections may be useful for future studies of CFTR modulators and bacterial acquisition in CF registry cohorts.
Details
- Title: Subtitle
- Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor
- Creators
- Sachinkumar B Singh - Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IowaAmanda J McLearn-Montz - Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, IowaFrancesca Milavetz - Department of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, IowaLevi K Gates - Department of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, IowaChristopher Fox - Department of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, IowaLogan T Murry - Department of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, IowaAshley Sabus - Department of Pharmacy Practice and Science, University of Iowa College of Pharmacy, Iowa City, IowaHarry S Porterfield - Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IowaAnthony J Fischer - Stead Family Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa
- Resource Type
- Journal article
- Publication Details
- Pediatric pulmonology, Vol.54(8), pp.1200-1208
- DOI
- 10.1002/ppul.24341
- PMID
- 31012285
- PMCID
- PMC6641998
- NLM abbreviation
- Pediatr Pulmonol
- ISSN
- 8755-6863
- eISSN
- 1099-0496
- Grant note
- K08 HL136927 / NHLBI NIH HHS NIH K08 HL136927 / NIH HHS HL136927 / NHLBI NIH HHS K12 HD027748-23 / NICHD NIH HHS L40 HL134155 / NHLBI NIH HHS K12 HD027748 / NICHD NIH HHS P30 DK054759 / NIDDK NIH HHS
- Language
- English
- Date published
- 08/2019
- Academic Unit
- Pulmonary Medicine; Stead Family Department of Pediatrics; Pharmacy Practice and Science
- Record Identifier
- 9984093338902771
Metrics
24 Record Views